NO20055099L - Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner - Google Patents

Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner

Info

Publication number
NO20055099L
NO20055099L NO20055099A NO20055099A NO20055099L NO 20055099 L NO20055099 L NO 20055099L NO 20055099 A NO20055099 A NO 20055099A NO 20055099 A NO20055099 A NO 20055099A NO 20055099 L NO20055099 L NO 20055099L
Authority
NO
Norway
Prior art keywords
quinolin
acetyl
hydroxy
haloacetyl
substituted
Prior art date
Application number
NO20055099A
Other languages
English (en)
Other versions
NO331980B1 (no
NO20055099D0 (no
Inventor
Gerhard Penn
Olivier Lohse
Hanspeter Schilling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33131902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055099(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20055099D0 publication Critical patent/NO20055099D0/no
Publication of NO20055099L publication Critical patent/NO20055099L/no
Publication of NO331980B1 publication Critical patent/NO331980B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Oppfinnelsen vedrøer en fremgangsmåte for fremstilling av 5-((-haloacetyl)-8-substitu-erte oks-(1H)-kinolin-2-oner. Fremgangsmåten omfatter (i) å reagere (a) 8-hydroksy-(1H)-kinolin-2-on med et acyleringsmiddel og en Lewis-syre for å danne 5-acetyl-8- hydroksy-(1H)-kinoli-2-on; eller (b) 8-hydroksy-(1H)-kinolin-2-on med et acyleringsmiddel for å danne 8-actoksy- (1H)-kinolin-2-on, og å behandle, in situ, 8-acetoksy-(1H)-kinolin-2-on med en Lewis-syre for å danne 5-acetyl-8-hydroksy-(1H)-kinolin-2-on; eller (c) 8-acetoksy-(1H)-kinolin-2-on med en Lewis-syre for å danne 5-acetyl-8-hydroksy-(1H)-kinolin-2-on; (ii) å reagere 5-acetyl-8-hydroksy-(1H)-kinolin-2-on fremstilt i trinn (i) med en forbindelse med formel RL i nærvær av en base og et løsningsmiddel for å danne 5-acetyl-8-substituert oksy-(1H)-kinolin-2-on, der R er en beskyttende gruppe og L er utgående gruppe; og (iii) å reagere det 5-acetyl-8-substituerte oksy-(1H)-kinolin-2-onet med et halogeneringsmiddel i nærvær av et løsningsmiddel for å danne et 5-((-haloacetyl)-8-substituert oksy-(1H)-kinolin-2-on.
NO20055099A 2003-04-02 2005-11-01 Fremgangsmate for fremstilling av 5 (¿-haloacetyl)-8-substituerte oksy-(1H)-kinolin-2-oner og 5-[(R)-2-(2,5-dietylindan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolon-2-on-salter NO331980B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45972403P 2003-04-02 2003-04-02
PCT/EP2004/003479 WO2004087668A1 (en) 2003-04-02 2004-04-01 A process for the preparation of 5-(haloacetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones

Publications (3)

Publication Number Publication Date
NO20055099D0 NO20055099D0 (no) 2005-11-01
NO20055099L true NO20055099L (no) 2006-01-02
NO331980B1 NO331980B1 (no) 2012-05-21

Family

ID=33131902

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055099A NO331980B1 (no) 2003-04-02 2005-11-01 Fremgangsmate for fremstilling av 5 (¿-haloacetyl)-8-substituerte oksy-(1H)-kinolin-2-oner og 5-[(R)-2-(2,5-dietylindan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolon-2-on-salter

Country Status (35)

Country Link
US (1) US7605267B2 (no)
EP (1) EP1613599B8 (no)
JP (1) JP4726778B2 (no)
KR (1) KR101073740B1 (no)
CN (1) CN1774423A (no)
AR (2) AR043825A1 (no)
AT (1) ATE491690T1 (no)
AU (1) AU2004226212B2 (no)
BR (1) BRPI0409154B1 (no)
CA (1) CA2520990C (no)
CL (1) CL2004000706A1 (no)
CO (1) CO5700779A2 (no)
CY (1) CY1111515T1 (no)
DE (1) DE602004030553D1 (no)
DK (1) DK1613599T3 (no)
EC (1) ECSP056059A (no)
ES (1) ES2358193T3 (no)
HK (1) HK1086833A1 (no)
HR (1) HRP20110184T1 (no)
IL (1) IL171053A (no)
IS (1) IS2800B (no)
MA (1) MA27761A1 (no)
MX (1) MXPA05010616A (no)
MY (1) MY141871A (no)
NO (1) NO331980B1 (no)
NZ (1) NZ542623A (no)
PE (2) PE20050211A1 (no)
PL (1) PL1613599T3 (no)
PT (1) PT1613599E (no)
RU (1) RU2339621C2 (no)
SI (1) SI1613599T1 (no)
TN (1) TNSN05245A1 (no)
TW (1) TWI324151B (no)
WO (1) WO2004087668A1 (no)
ZA (1) ZA200507603B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
SI2044025T1 (sl) 2006-06-30 2013-01-31 Novartis Ag Kinolinonski derivati in njihovi farmacevtski sestavki
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
CN102633717B (zh) * 2012-03-30 2013-11-20 西南大学 N-乙酰-喹啉-2(1h)酮类化合物及其制备方法和应用
CN104379566B (zh) * 2012-07-11 2016-08-24 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
PL3092217T3 (pl) 2014-01-09 2020-11-16 Davuluri, Ramamohan Rao Nowy sposób wytwarzania indakaterolu lub jego farmaceutycznie dopuszczalnych soli
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
WO2016161956A1 (zh) * 2015-04-09 2016-10-13 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN114751857A (zh) * 2022-04-29 2022-07-15 梯尔希（南京）药物研发有限公司 一种茚达特罗杂质的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS539228B2 (no) * 1974-01-31 1978-04-04
CA1164459A (en) * 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
JPS5896022A (ja) * 1981-11-30 1983-06-07 Otsuka Pharmaceut Co Ltd 強心剤
ES8403457A1 (es) * 1983-01-28 1984-03-16 Espanola Farma Therapeut Procedimiento para la obtencion de un compuesto derivado de la 2-quinolinona.
ES8605239A1 (es) * 1985-12-04 1986-03-16 Astur Pharma Un procedimiento para la preparacion de quinolonas sustitui-das
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt

Also Published As

Publication number Publication date
PE20100399A1 (es) 2010-06-01
WO2004087668A1 (en) 2004-10-14
US20060189653A1 (en) 2006-08-24
EP1613599A1 (en) 2006-01-11
MA27761A1 (fr) 2006-02-01
ECSP056059A (es) 2006-01-27
NO331980B1 (no) 2012-05-21
CY1111515T1 (el) 2015-08-05
EP1613599B8 (en) 2011-06-22
MXPA05010616A (es) 2005-11-23
BRPI0409154A (pt) 2006-03-28
HK1086833A1 (en) 2006-09-29
IS8095A (is) 2005-10-27
ATE491690T1 (de) 2011-01-15
ZA200507603B (en) 2006-11-29
NO20055099D0 (no) 2005-11-01
CA2520990C (en) 2011-08-09
PL1613599T3 (pl) 2011-05-31
DK1613599T3 (da) 2011-03-28
IS2800B (is) 2012-09-15
RU2339621C2 (ru) 2008-11-27
NZ542623A (en) 2008-07-31
CL2004000706A1 (es) 2005-01-14
JP4726778B2 (ja) 2011-07-20
MY141871A (en) 2010-07-16
TWI324151B (en) 2010-05-01
CA2520990A1 (en) 2004-10-14
AU2004226212B2 (en) 2008-02-21
US7605267B2 (en) 2009-10-20
AR043825A1 (es) 2005-08-17
TW200504025A (en) 2005-02-01
KR20050119678A (ko) 2005-12-21
JP2006522055A (ja) 2006-09-28
AU2004226212A1 (en) 2004-10-14
IL171053A (en) 2010-12-30
PT1613599E (pt) 2011-03-17
PE20050211A1 (es) 2005-04-27
SI1613599T1 (sl) 2011-04-29
DE602004030553D1 (de) 2011-01-27
EP1613599B1 (en) 2010-12-15
HRP20110184T1 (hr) 2011-04-30
BRPI0409154B1 (pt) 2014-03-25
CN1774423A (zh) 2006-05-17
KR101073740B1 (ko) 2011-10-13
ES2358193T3 (es) 2011-05-06
CO5700779A2 (es) 2006-11-30
AR103508A2 (es) 2017-05-17
TNSN05245A1 (en) 2007-06-11

Similar Documents

Publication Publication Date Title
NO20055099L (no) Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner
Savini et al. Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones
RS107604A (en) Process for the manufacture of quinoline derivatives
HRP20060124A2 (en) Process for the preparation of n-amino substituted heterocyclic compounds
NO20082243L (no) Fremgangsmater og forbindelser for fremstiliing av CC-1065 analoger
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
WO2003072553A8 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
WO2009146218A3 (en) Compounds including an anti-inflammatory pharmacore and methods of use
NO20082719L (no) Aryl-isoksazol-4-yl-oksadiazolderivater
CA2533685A1 (en) Nitrogen-containing fused heterocyclic carboxylic acid compounds
NO20072165L (no) Metabolitter av visse (1,4)diazepino(6,7,1-IJ)kinolinderivater og fremgangsmater for fremstilling og anvendelse derav
NO20092076L (no) Ny fremgangsmate for fremstilling av 4,4'-(1-metyl-1,2-etandiyl)-bis-(2,6-piperazindion)
NO20032667L (no) Cykliseringsfremgangsmåtetrinn for fremstilling av kinoloner og naftyridiner
DE60036076D1 (de) Verfahren zur herstellung eines piperazinderivates
WO2007039117A3 (en) A process for the preparation of sartan derivatives and intermediates useful in such process
NO20023505L (no) Fremgangsmåte for fremstilling av quinolylakrylonitril og intermediater derfor
NO20053712L (no) Fremgangsmate for fremstilling av substituerte imidazolderivater og mellomprodukter anvendt i fremgangsmaten
CR7832A (es) Tritiocarbonatos de cianometilo como nematicidas
WO2001083423A3 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof
CY1107157T1 (el) Παραγωγα 4-οξο-4,6,7,8-τετραϋδροπυρρολο 1,2-a πυραζινο-6-καρβοξαμιδων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν
TW200730495A (en) Process for producing 2-oxindole compound
HUP0202296A2 (hu) Eljárás szubsztituált benzizotiazolszármazékok előállítására